You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 8,440,622


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,440,622
Title:Use of gelsolin to treat multiple sclerosis and to diagnose neurologic disease (stossel)
Abstract: The invention relates to the use of gelsolin to treat neurologic diseases (e.g., multiple sclerosis) and to the use of gelsolin to diagnose, monitor, and evaluate therapies of neurologic diseases.
Inventor(s): Stossel; Thomas P. (Belmont, MA), Lee; Po-Shun (Brookline, MA), Dittel; Bonnie (Whitefish Bay, WI), Maresz; Katarzyna (Cracow, PL)
Assignee: The Brigham and Women\'s Hospital, Inc. (Boston, MA) BloodCenter Research Foundation, Inc. (Milwaukee, WI)
Application Number:12/225,132
Patent Claims:1. A method for treating a subject to prevent or suppress the manifestations of multiple sclerosis comprising: selecting a subject who has multiple sclerosis and who has a below-normal level of plasma gelsolin and administering plasma gelsolin to the subject in an effective amount to prevent or suppress the manifestations of multiple sclerosis.

2. The method of claim 1, wherein the subject is otherwise free of indications calling for treatment with plasma gelsolin.

3. The method of claim 1, wherein the multiple sclerosis is acute, relapsing, remitting, stable, chronic, or probable.

4. The method of claim 1, wherein the plasma gelsolin is administered orally, sublingually, buccally, intranasally, intravenously, intramuscularly, intrathecally, intraperitoneally, or subcutaneously.

5. The method of claim 1, wherein the plasma gelsolin is administered prophylactically.

6. The method of claim 1 further comprising administering a second agent for treating multiple sclerosis.

7. The method of claim 6, wherein the second agent is interferon (IFN)-.beta.1b (Betaseron or Betaferon), IFN-.beta.1a (Avonex, Rebif), glatiramer acetate (Copaxone), mitoxantrone (Novantrone), azathioprine, cyclosporine, methotrexate, cyclophosphamide, intravenous immunoglobulin, prednisone, methylprednisone, prednisolone, methylprednisolone, dexamethasone, adreno-corticotrophic hormone (ACTH), corticotropin, 2-chlorodexyadenosine (2-CDA, cladribine), inosine, Interleukin-2antibody (Zenapax, daclizumab), leucovorin, teriflunomide, estroprogestins, desogestrel, etinilestradiol, BHT-3009, ABT-874, Bacille Calmette-Guerin (BCG) Vaccine, T cell vaccination, CNTO 1275, Rituximab, Tysabri (natalizumab), N-acetylcysteine, minocycline, RO0506997, or a statin.

8. The method of claim 1, wherein the below-normal level of plasma gelsolin is at or about 250 mg/L of plasma.

9. A method for treating a subject to prevent or suppress the manifestations of multiple sclerosis comprising: selecting a subject who has multiple sclerosis and who has a below-normal level of plasma gelsolin and administering plasma gelsolin to the subject in an effective amount to raise the level of gelsolin in the subject above a predetermined value.

10. The method of claim 9, wherein the subject is otherwise free of indications calling for treatment with plasma gelsolin.

11. The method of claim 9, wherein the multiple sclerosis is acute, relapsing, remitting, stable, chronic, or probable.

12. The method of claim 9, wherein the plasma gelsolin is administered orally, sublingually, buccally, intranasally, intravenously, intramuscularly, intrathecally, intraperitoneally, or subcutaneously.

13. The method of claim 9, wherein the plasma gelsolin is administered prophylactically.

14. The method of claim 9 further comprising administering a second agent for treating multiple sclerosis.

15. The method of claim 14, wherein the second agent is interferon (IFN)-.beta.1b (Betaseron or Betaferon), IFN-.beta.1a (Avonex, Rebif), glatiramer acetate (Copaxone), mitoxantrone (Novantrone), azathioprine, cyclosporine, methotrexate, cyclophosphamide, intravenous immunoglobulin, prednisone, methylprednisone, prednisolone, methylprednisolone, dexamethasone, adreno-corticotrophic hormone (ACTH), corticotropin, 2-chlorodexyadenosine (2-CDA, cladribine), inosine, Interleukin-2antibody (Zenapax, daclizumab), leucovorin, teriflunomide, estroprogestins, desogestrel, etinilestradiol, BHT-3009, ABT-874, Bacille Calmette-Guerin (BCG) Vaccine, T cell vaccination, CNTO 1275, Rituximab, Tysabri (natalizumab), N-acetylcysteine, minocycline, RO0506997, or a statin.

16. The method of claim 9 further comprising performing one or more tests to evaluate the multiple sclerosis.

17. The method of claim 9, wherein the below-normal level of plasma gelsolin is at or about 250 mg/L of plasma.

Details for Patent 8,440,622

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Teknika Llc N/A bcg vaccine For Injection 103050 06/21/1989 ⤷  Try a Trial 2026-03-15
Bayer Healthcare Pharmaceuticals Inc. BETASERON interferon beta-1b For Injection 103471 07/23/1993 ⤷  Try a Trial 2026-03-15
Biogen Inc. AVONEX interferon beta-1a For Injection 103628 05/17/1996 ⤷  Try a Trial 2026-03-15
Biogen Inc. AVONEX interferon beta-1a Injection 103628 05/28/2003 ⤷  Try a Trial 2026-03-15
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.